Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage

U.S. FDA approved Eisai's intravenous sedative-hypnotic agent Lusedra (fospropofol), but without the marketing advantage the company was hoping it would used to help differentiate the anesthetic from its competitors